Table 2.

Incidence of treatment-emergent adverse events (safety population)

TEAEs, n (%)	Clobetasol propionate 0.025% cream						Clobetasol propionate 0.05% cream (N = 30)
	Formulation 5 (N = 29)			Formulation 13 (N = 29)
	Total	Treatment related	Probably related	Total	Treatment related	Probably related	Total	Treatment related	Probably related
Patients with at least 1 TEAE	13 (44.8)	0	12 (41.4)	15 (50.0)	0	10 (34.5)	15 (50.0)	0	11 (36.7)
TEAEs in > 3% of patients	0	0	0	0	0	0	2 (6.7)	0	0
Pain	0	0	0	0	0	0	1 (3.3)	0	0
Pyrexia	0	0	0	0	0	0	1 (3.3)	0	0
Gastroenteritis	0	0	0	0	0	0	1 (3.3)	0	0
Nasopharyngitis	0	0	0	0	0	0	2 (6.7)	0	0
Tinea cruris	0	0	0	0	0	0	1 (3.3)	0	0
Blood cortisol decrease	13 (44.8)	0	12 (41.4)	11 (37.9)	0	10 (34.5)	11 (36.7)	0	11 (36.7)
Cough	0	0	0	0	0	0	2 (6.7)	0	0
Pruritus	1 (3.4)	0	0	0	0	0	1 (3.3)	0	0
Telangiectasia	0	0	0	0	0	0	1 (3.3)	0	1 (3.3)

	Mild	Moderate	Severe	Mild	Moderate	Severe	Mild	Moderate	Severe
Proportion of patients with mild, moderate, and severe
Patients with at least 1 TEAE	11 (37.9)	2 (6.9)	1 (3.4)	7 (24.1)	3 (10.3)	1 (3.4)	9 (30.0)	6 (20.0)	3 (10.0)
Pain	0	0	0	0	0	0	0	0	1 (3.3)
Pyrexia	0	0	0	0	0	0	1 (3.3)	0	0
Gastroenteritis	0	0	0	0	0	0	1 (3.3)	0	0
Nasopharyngitis	0	0	0	0	0	0	0	2 (6.7)	0
Tinea cruris	0	0	0	0	0	0	1 (3.3)	0	0
Blood cortisol decrease	10 (34.5)	2 (6.9)	1 (3.4)	7 (24.1)	3 (10.3)	1 (3.4)	6 (20.0)	4 (13.3)	1 (3.3)
Hyperglycemia	1 (3.4)	0	0	0	0	0	0	0	0
Cough	0	0	0	0	0	0	2 (6.7)	0	0
Pruritus	1 (3.4)	0	0	0	0	0	0	0	1 (3.3)
Telangiectasia	0	0	0	0	0	0	1 (3.3)	0	0

TEAEs treatment-emergent adverse events.